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Although childhood arterial ischemic stroke (AIS) is a het-erogeneous disorder, most cases fall into 1 of 3 broad 
pathogenic categories: arteriopathic, cardioembolic, and idio-
pathic.1 The presence of an arteriopathy (cervical or cerebral) 
confers an increased risk of recurrent AIS.2–5 In the prospec-
tive, multicenter VIPS study (Vascular Effects of Infection 
in Pediatric Stroke), children with arteriopathic stroke had 
a 21% (95% confidence interval [CI], 14%–29%) chance of 
recurrence within 1 year compared with 8% (95% CI, 3–18) 
with cardioembolic and 5% (95% CI, 2–12) with idiopathic 
stroke.2 Childhood arteriopathies are themselves heteroge-
neous and poorly understood,6 yet mounting evidence suggests 
that infection and inflammation play a role in their patho-
genesis. The VIPS study, and others, provide evidence that 
acute infection, such as the common cold or herpesviruses, 
act as triggers for childhood AIS.7–10 Arterial wall imaging 
Background and Purpose—Among children with arterial ischemic stroke (AIS), those with arteriopathy have the highest 
recurrence risk. We hypothesized that arteriopathy progression is an inflammatory process and that inflammatory 
biomarkers would predict recurrent AIS.
Methods—In an international study of childhood AIS, we selected cases classified into 1 of the 3 most common childhood AIS 
causes: definite arteriopathic (n=103), cardioembolic (n=55), or idiopathic (n=78). We measured serum concentrations 
of high-sensitivity C-reactive protein, serum amyloid A, myeloperoxidase, and tumor necrosis factor-α. We used linear 
regression to compare analyte concentrations across the subtypes and Cox proportional hazards models to determine 
predictors of recurrent AIS.
Results—Median age at index stroke was 8.2 years (interquartile range, 3.6–14.3); serum samples were collected at median 
5.5 days post stroke (interquartile range, 3–10 days). In adjusted models (including age, infarct volume, and time to sample 
collection) with idiopathic as the reference, the cardioembolic (but not arteriopathic) group had higher concentrations 
of high-sensitivity C-reactive protein and myeloperoxidase, whereas both cardioembolic and arteriopathic groups had 
higher serum amyloid A. In the arteriopathic (but not cardioembolic) group, higher high-sensitivity C-reactive protein 
and serum amyloid A predicted recurrent AIS. Children with progressive arteriopathies on follow-up imaging had higher 
recurrence rates, and a trend toward higher high-sensitivity C-reactive protein and serum amyloid A, compared with 
children with stable or improved arteriopathies.
Conclusions—Among children with AIS, specific inflammatory biomarkers correlate with cause and—in the arteriopathy 
group—risk of stroke recurrence. Interventions targeting inflammation should be considered for pediatric secondary 
stroke prevention trials.   (Stroke. 2016;47:2221-2228. DOI: 10.1161/STROKEAHA.116.013719.)
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studies detecting enhancement in the wall of affected vessels 
in childhood arteriopathies may suggest an acute inflamma-
tory process.11,12 Children whose arteriopathies progress after 
their index stroke have the highest risk of recurrent AIS.13,14 
We hypothesized that arteriopathy progression is an inflam-
matory process and that markers of inflammation would pre-
dict recurrent AIS in childhood. To explore this hypothesis, 
we measured serum levels of 4 soluble immune mediators in 
children with AIS enrolled in the VIPS study: high-sensitivity 
C-reactive protein (hsCRP), serum amyloid A (SAA), myelo-
peroxidase, and tumor necrosis factor (TNF)-α. These 4 ana-
lytes were selected because of their published associations 
with adult stroke and vascular disease.15,16
Methods
Study Subjects and Sample Collection
The VIPS study prospectively enrolled and centrally confirmed 355 
children (29 days to 19 years) with AIS at 37 international sites from 
January 2010 to March 2014. Details of our methods for enrollment, 
case confirmation, data collection, classification of cause, parental 
interview, sample collection, and ascertainment and confirmation of 
recurrent AIS are published.2,6–8,17 In brief, a team of pediatric stroke 
neurologists and neuroradiologists confirmed cases after central 
review of imaging and clinical features. A single neuroradiologist 
(M.W.) estimated infarct volume using the ABC/2 method.18 A cen-
tral team similarly reviewed all clinically obtained cerebrovascular 
imaging and clinical data to classify cases as definite, possible, or no 
arteriopathy; no arteriopathy cases were further classified into car-
dioembolic, other specific cause, or idiopathic.6 When arteriopathic 
cases had follow-up imaging, the team classified evolution as stable, 
improves or resolves, progresses, or progresses then improves or 
resolves. For analysis, these categories were dichotomized as stable/
improving/resolved versus progression (regardless of subsequent 
improvement). The study protocol included a minimum follow-up of 
1 year. Recurrent AIS, defined as a new acute infarction in an arte-
rial territory with corresponding new or worsening clinical signs and 
symptoms, was centrally confirmed.2
Laboratory Methods
Blood samples were collected locally as soon as possible after enroll-
ment, up to 21 days post stroke. They were centrifuged at 3000 rpm 
for 10 minutes, with serum samples immediately separated, ali-
quoted, and stored in 1.2-mL cryovials at −70°C. Samples were then 
shipped on dry ice to the Center for Advanced Laboratory Medicine at 
Columbia University and were run in batches by technicians blind to 
clinical status. hsCRP and SAA concentrations were measured using 
a clinically validated BNII nephelometer (Siemens Dade Behring, 
Deerfield, IL). TNF-α (Invitrogen, Camarillo, CA) and myeloper-
oxidase (R&D Systems Inc, Minneapolis, MN) concentrations were 
measured using ELISA following the manufacturer’s instructions. 
Assay performance was within the manufacturer’s specifications.
Data Analysis
Analysis focused on cases that could be classified with a high degree 
of certainty into 1 of the 3 most common pathogenic groups: arte-
riopathic, cardioembolic, or idiopathic (Figure 1). From the overall 
VIPS cohort of 355 children, we excluded those with possible arteri-
opathy (likely a mixture of causes)6 or other specific causes not fall-
ing into the 3 major categories of interest. We also excluded cases 
with major infections (sepsis, meningitis/encephalitis, and endocar-
ditis) that would impact serum concentrations of inflammatory bio-
markers. We compared analyte concentration levels in the remaining 
children. Kruskal–Wallis tests were used to make unadjusted compar-
isons of each analyte individually across the 3 pathogenic groups: lin-
ear regression models examined the associations between individual 
analytes and stroke cause while adjusting for potential confounders 
(age, sex, infarct volume, time from stroke to blood sampling, sei-
zures at presentation, and clinical infection in the week preceding 
stroke). For regression analyses, analyte concentration levels were 
used as outcomes and log-transformed to reduce the skewness of 
residuals; our primary predictor was pathogenic group with idio-
pathic as a reference.
To assess variables related to risk of recurrent AIS, we used sur-
vival analysis techniques as previously described; the outcome was 
defined as the time from index AIS to first recurrent AIS and cases 
were censored at death or loss to follow-up.2 To determine whether 
analyte concentrations correlated with recurrent AIS, we created Cox 
proportional hazards models. Each analyte was analyzed individu-
ally to determine its potential association with recurrence. Analyte 
concentrations were log-base 2 transformed to yield relative hazards 
associated with a doubling of concentration. We adjusted for stroke 
cause, as well as those variables included in the linear regression 
models above. To investigate potential interactions by stroke cause, 
we included an interaction term in our Cox models and performed 
analyses stratified by subtype. Only the arteriopathic and cardio-
embolic subgroups were assessed in these analyses because of the 
paucity of outcomes (recurrence) in the idiopathic group. Among the 
subgroup of children with arteriopathic stroke and follow-up vascu-
lar imaging, we analyzed arteriopathy progression as a dichotomous 
predictor of recurrent AIS; to maintain consistency across models, we 
adjusted for the potential confounders described above. Our α-level 
was set at 0.05. All analyses were conducted using Stata v12 (Stata 
Corp, College Station, TX).
Results
The present analysis included 236 children with AIS whose 
cause was classified into 1 of the 3 major groups (Figure 1): 
idiopathic (n=78), arteriopathic (n=103), and cardioembolic 
(n=55). Median age at stroke ictus was 8.2 years overall (inter-
quartile range [IQR], 3.6, 14.3) and was higher in the idiopathic 
Figure 1. Flow diagram showing the 236 VIPS (Vascular Effects 
of Infection in Pediatric Stroke) cases included in the current 
analysis. AIS indicates arterial ischemic stroke. *No significant 
difference in age, sex, or cause compared with cases with  
serum sample. †Hypercoagulable condition (n=5), sickle cell  
disease (n=4), head trauma (n=3), cancer (n=3), and genetic 
 disorder (n=3).
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group (11.8) than in the arteriopathic (7.5) or cardioembolic 
(5.1) groups (P=0.07); 134 (57%) were boys. The median time 
from stroke ictus to collection of the serum sample was 5.5 days 
(IQR, 3–10 days); we included 4 samples collected beyond the 
21-day window (Figure 2). Concentrations of hsCRP and SAA 
correlated with infarct size, but myeloperoxidase and TNF-α 
did not (Figure I in the online-only Data Supplement).
Inflammatory Markers and Stroke Cause
In our unadjusted analyses, there were significant differences 
in all analyte concentrations across all the 3 pathogenic groups 
(Table 1). In the adjusted models, compared with children 
with idiopathic stroke, children with cardioembolic stroke had 
higher concentrations of 3 analytes (hsCRP, SAA, and myelo-
peroxidase), whereas those with arteriopathic stroke had 
higher levels of only 1 analyte, SAA (adjustment for seizures 
and infection in the preceding week had minimal impact on 
the models; data not shown).
Inflammatory Markers and Recurrent AIS
The 236 children were followed up for a median of 23 months 
(range, 7 days to 60 months) after index stroke. During fol-
low-up, 31 children had a recurrent AIS: 24 (23%) of 103 in 
the arteriopathic group, 5 (9%) of 55 in the cardioembolic 
group, and 2 (3%) of 78 in the idiopathic group. Higher con-
centrations of 2 analytes—hsCRP and SAA—were associated 
with an increased hazard of recurrent AIS in children with 
arteriopathic, but not with cardioembolic stroke (Table 2; test 
for interaction, P=0.87 for hsCRP and P=0.31 for SAA). The 
effect size was similar for both analytes: doubling of their con-
centrations increased the hazard of recurrence after arterio-
pathic AIS by 16% (Table 2). Cumulative recurrence risk after 
arteriopathic AIS, stratified by analyte concentration above 
versus below the median, is shown in Figure 3A and 3B. The 
2 markers were highly collinear (r=0.82; P<0.0001), so could 
not be included in the same Cox model.
Arteriopathy Progression and Recurrent AIS
Among the 103 children with arteriopathic stroke, 62 (60%) 
had centrally reviewed follow-up vascular imaging (Table I 
in the online-only Data Supplement). The median time from 
index stroke to final vascular imaging included in these analy-
ses was 5 months (IQR, 1–12 months). The arteriopathy was 
classified as progressive in 30 (48%) and nonprogressive 
(stable or improved) in 32 (52%). In an analysis of these 62 
children, arteriopathy progression increased the hazard of 
recurrent AIS 3-fold (adjusted hazard ratios, 3.1; 95% CI, 1.1–
8.7; P=0.036). Among children with progressive arteriopathy, 
the 1-year cumulative risk of recurrence was 46% (95% CI, 
25–84) compared with 25% (95% CI, 12–52) among those 
with nonprogressive arteriopathy (Figure 3C).
Inflammatory Markers and 
Arteriopathy Progression
The median hsCRP concentration was 1.62 mg/L (IQR, 0.46–
7.28) in the progressive group (n=28) compared with 0.87 
mg/L (IQR, 0.16–4.13) in the nonprogressive group (n=31; 
unadjusted P=0.20, Wilcoxon rank-sum test). The median 
SAA concentration was 14.2 mg/L (IQR, 1.7–59) in the pro-
gressive group (n=29) compared with 3.9 mg/L (IQR, 1.4–
13.3) in the nonprogressive group (n=29; unadjusted P=0.067, 
Wilcoxon rank-sum test). Adjusted linear regression models 
did not find significant associations between arteriopathy 
progression and log-transformed concentrations of hsCRP 
(P=0.283) and SAA (P=0.089).
Discussion
In a large, international study of childhood AIS, serum con-
centrations of 3 of 4 measured inflammatory biomarkers 
differed by stroke cause, even after adjusting for potential 
confounders. Two of these—the acute phase reactants CRP 
and SAA—predicted risk of recurrent AIS among children 
with arteriopathic stroke, the subgroup at highest risk for 
recurrence. Children with progressive arteriopathies had the 
highest recurrence risk and a trend toward higher hsCRP and 
SAA concentrations. These findings have important impli-
cations for the development of new strategies for secondary 
stroke prevention in childhood.
Two previous studies of childhood AIS, the Swiss 
Neuropediatric Stroke Registry Study Group (n=12 cases, n=7 
controls) and a single-center US study (n=50 cases), measured 
serum levels of inflammatory biomarkers; both found elevated 
hsCRP, whereas other markers, including TNF-α, were not 
significantly different.19,20 Elevations in these serum markers 
measured poststroke could reflect, in part, downstream effects 
of the infarct itself related to tissue destruction and break-
down of the blood–brain barrier. Because we could collect 
only poststroke serum samples, we adjusted our analyses for 
infarct size, seizures, and timing of the serum sample relative 
to the stroke. Although residual confounders may exist, sev-
eral pieces of evidence indicate that these markers also reflect 
upstream mechanisms underlying the stroke pathogenesis. 
First, adult studies similarly found that serum levels of soluble 
immune mediators (TNF-α, interleukin-6, and interleukin-1β) 
correlate with stroke cause.21,22 Second, we observed large vari-
ations in biomarker concentrations even among children with 
low volume infarcts that should have had minimal systemic 
effects (Figure I in the online-only Data Supplement). Third, 
Figure 2. Histogram demonstrating time in days from stroke ictus 
to serum sample collection (n=236).
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the observed associations between biomarkers and recurrence 
risk in the arteriopathic group suggest that inflammation may 
be contributing to the pathogenesis of subsequent strokes.
Systemic inflammation could play a complex role in AIS 
pathogenesis. Circulating immune mediators can activate the 
coagulation system, promoting thrombosis, and can injure 
arterial and cardiac endothelium.23 The different patterns of 
immune activation we observed across our 3 etiologic sub-
groups suggest that inflammation may play different roles 
in different childhood stroke causes. We speculate that sys-
temic inflammation interacts with other pediatric stroke risk 
factors, like congenital heart disease and trauma. In a child 
with a structurally abnormal heart, inflammation might trigger 
intracardiac thrombus formation and cardioembolic stroke. 
Inflammation might make the cervical arteries more vulner-
able to dissection; exposure to trauma after arteries have been 
primed by inflammation could trigger arteriopathic stroke.
The link between inflammation, arteriopathy, and stroke 
recurrence in childhood has previously been postulated, but 
never directly studied.12,20 Arterial wall imaging studies sug-
gest that some childhood arteriopathies may be inflammatory 
in nature.11,12 Other studies have reported a correlation between 
arteriopathy progression and increased risk of recurrence.13,14 
We confirmed that children with progressive arteriopathy have 
the highest risk of recurrent AIS: almost half had a recurrence 
within 1 year, most within the first 30 days, compared with 
12% of the VIPS cohort overall.2 We demonstrated for the first 
time that higher levels of 2 inflammatory biomarkers (hsCRP 
and SAA) correlate with higher recurrence risk after arte-
riopathic stroke, particularly in the first 60 days (Figure 3A 
and 3B). We observed a trend toward a correlation between 
those markers and arteriopathy progression (but were likely 
underpowered because only a subset of cases had follow-up 
vascular imaging). Although our observational data can dem-
onstrate only correlation, and not causation, we hypothesize 
that arteriopathy progression results from ongoing inflamma-
tion of the affected arteries. This hypothesis could be tested in 
a randomized controlled trial of anti-inflammatory therapy for 
secondary stroke prevention in childhood. Such a trial design, 
however, would need to consider the role of infection and 
other factors in pathogenesis, and the concern for immuno-
suppression in the setting of acute infection.
The 4 specific immune mediators we measured provide a 
window into a complex immune response. SAA concentra-
tions were elevated in both our arteriopathic and cardioem-
bolic cases and correlated with recurrence in the arteriopathic 
group. SAA is not only a biomarker but also a participant in the 
innate immune response. It promotes adhesion, migration, and 
infiltration of lymphocytes and monocytes; regulates produc-
tion of cytokines by inflammatory cells; and increases genera-
tion of extracellular matrix metalloproteinases.24,25 Through 
these effects, SAA plausibly participates in damage to arte-
rial or cardiac endothelium that may be relevant to childhood 
stroke. SAA is elevated in adults with both Takayasu arteritis 
and giant cell arteritis and correlates with disease activity of 
inflammatory arteriopathies.26,27
Table 1. Levels of Inflammatory Markers in Children With Idiopathic, Arteriopathic, and Cardioembolic Arterial Ischemic Stroke
Idiopathic Arteriopathic Cardioembolic
Unadjusted P Value†n Median (IQR) n Median (IQR) Adjusted P Value* n Median (IQR) Adjusted P Value*
hsCRP, mg/L 78 0.48 (0.18–2.5) 100 1.1 (0.28–6.1) 0.071 54 4.6 (1.5–14) <0.0001 0.0001
SAA, mg/L 77 4.1 (1.3–8.4) 97 6.9 (1.8–33) 0.042 52 7.7 (2.3–32) 0.049 0.007
MPO, ng/mL 78 156 (87–342) 103 158 (73–258) 0.21 55 327 (154–532) 0.004 0.0001
TNF-α, pg/mL 78 2.6 (1.0–4.1) 103 2.4 (0.47–3.4) 0.53 55 3.3 (1.6–4.5) 0.09 0.03
hsCRP indicates high-sensitivity C-reactive protein; IQR, interquartile range; MPO, myeloperoxidase; SAA, serum amyloid A; and TNF, tumor necrosis factor.
*From linear regression models using log-transformed outcomes and adjusted for age, sex, infarct volume, time from stroke to blood sample, seizure, and clinical 
infection in preceding week; reference is idiopathic.
†Kruskal–Wallis tests across all 3 groups.
Table 2. Adjusted HR* for Inflammatory Markers as a Predictor of Recurrent Arterial Ischemic Stroke in Children With Arterial 
Ischemic Stroke
Marker†
Overall (29 Recurrences) Arteriopathic (24 Recurrences) Cardioembolic (5 Recurrences)
n HR (95% CI) Adjusted P Value* n HR (95% CI) Adjusted P Value* n HR (95% CI) Adjusted P Value*
hsCRP, mg/L 151 1.13 (0.99–1.28) 0.06 98 1.16 (1.01–1.32) 0.034 53 0.93 (0.63–1.43) 0.73
SAA, mg/L 147 1.11 (0.96–1.28) 0.15 97 1.16 (1.001–1.35) 0.048 52 0.49 (0.20–1.22) 0.12
MPO, ng/mL 155 1.08 (0.81–1.43) 0.58 101 1.13 (0.81–1.56) 0.47 54 0.92 (0.45–1.90) 0.83
TNF-α, pg/mL 155 1.21 (0.96–1.95) 0.12 101 1.12 (0.90–1.39) 0.3 53 1.44 (0.56–3.74) 0.45
CI indicates confidence interval; HR, hazard ratio; hsCRP, high-sensitivity C-reactive protein; MPO, myeloperoxidase; SAA, serum amyloid A; and TNF, tumor necrosis 
factor.
*From Cox proportional hazards models adjusted for age, sex, infarct volume, time to blood sample, seizure, and clinical infection in preceding week. Overall models 
include, and are adjusted for, cardioembolic and arteriopathic stroke subtype; idiopathic strokes were excluded because of the extremely low rate of recurrence in this 
group.
†All marker concentrations were converted to log-base 2 for analysis. HRs are interpreted as the relative hazard of recurrence risk associated with a doubling of the 
marker.
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hsCRP was significantly elevated only in our cardioem-
bolic cases although there was a trend toward higher levels 
in arteriopathic cases. Levels also correlated with recurrence 
risk in the arteriopathic group. CRP is an acute phase reac-
tant used clinically as a nonspecific marker of inflammation; 
it predicts a broad variety of cardiovascular and noncardiovas-
cular causes of morbidity and mortality, including adult AIS, 
prognosis after stroke, and atherosclerosis.28–30 Mounting evi-
dence indicates that CRP, like SAA, is not only a biomarker 
but also a participant in the innate immune response.31,32 The 
aforementioned Swiss study reported higher median hsCRP 
levels in their 12 cases of childhood AIS (median, 5.9 μg/mL; 
range, 0.13–98) than 7 age-matched control children (median, 
0.12 μg/mL; range 0.003, 4.1; P=0.007).19 The single-center 
US study of childhood AIS reported similar median CRP con-
centrations for cardioembolic (n=11) and arteriopathic (n=26) 
subtypes compared with our study, but was underpowered to 
detect a significant difference.20 Regardless, the nonspecificity 
of CRP may limit its utility in distinguishing among mecha-
nisms of stroke subtype, whereas it may still be useful as a 
marker of recurrent stroke risk among children with arterio-
pathic stroke.
Figure 3. (Continued )
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Myeloperoxidase was elevated in our cardiac cases 
and did not seem important in our arteriopathic cases. 
Myeloperoxidase levels correlate with active coronary 
artery disease, predicting risk of myocardial infarction.16 
Atherosclerosis and coronary artery disease are unlikely to 
be contributors to stroke risk in children, but other childhood 
cardiac disorders are associated with stroke risk and could 
explain some of the association with myeloperoxidase. TNF-
α, which has been associated with cardioembolic stroke in 
adults,21,22 neither correlate with either stroke cause or recur-
rence in our pediatric study nor was it elevated in the cases 
of childhood AIS in the Swiss study.19 TNF-α is a less stable 
marker in stored specimens, however, and associations may 
thus be limited by measurement error.
In addition to the limitation of having only poststroke 
serum samples available for analysis, our study has many 
other limitations. Although VIPS is the largest-ever prospec-
tive study of childhood AIS, some of our analyses may have 
been underpowered to detect actual differences between 
groups. Because we had only clinically obtained imaging, 
our analyses of arteriopathy progression were likely biased 
as children are more likely to get follow-up imaging if they 
have a recurrent stroke. Hence, our estimates of stroke recur-
rence among children with arteriopathy progression and 
nonprogression were likely overestimates. For feasibility 
of enrollment, our blood samples were collected alongside 
clinical phlebotomy over a 3-week window after the stroke; 
late samples may have been less likely to reflect prestroke 
inflammatory processes. Published pediatric normative val-
ues for most of our analytes are not available, and we did 
not have serum samples from healthy control children. The 
VIPS study collected blood samples only from trauma con-
trols (for antibody titers), and the trauma would likely have 
affected the inflammatory biomarker concentrations. Finally, 
we measured only 4 biomarkers; since our study began, more 
immune mediators have been linked to stroke and vascular 
injury.23 The renewal of the VIPS study proposes to address 
many of these limitations by collecting serum samples in a 
shorter time window (72 hours post stroke), using multiplex 
technology to analyze a large number of inflammatory mark-
ers and collecting serum samples from well children under-
going elective procedures.
Conclusions
Different inflammatory responses may underlie the heteroge-
neity in childhood stroke pathogenesis and recurrent stroke 
risk. Because children with progressive arteriopathies have 
the highest risk of recurrent AIS, a better understanding of 
the inflammatory processes underlying their arteriopathies 
will guide the development of secondary stroke prevention 
strategies.
Appendix
Michael M. Dowling (University of Texas Southwestern Medical 
Center, Dallas), Susan L. Benedict (Primary Children’s Medical 
Center, Salt Lake City), Timothy J. Bernard (Denver Children’s 
Hospital), Christine K. Fox (UCSF), Gabrielle A. deVeber (The 
Hospital for Sick Children, Toronto), Neil R. Friedman (Cleveland 
Clinic Children’s Hospital), Warren D. Lo (The Ohio State 
University and Nationwide Children’s Hospital, Columbus OH), 
Rebecca N. Ichord (Children’s Hospital of Philadelphia), Marilyn 
A. Tan (University of the Philippines-Philippine General Hospital, 
Manila), Mark T. Mackay (Royal Children’s Hospital Melbourne), 
Figure 3 Continued. Nelson–Aalen plots demonstrating cumulative incidence of recurrent arterial ischemic stroke (AIS) after index arte-
riopathic AIS. A and B, Recurrence for children with definite arteriopathy stratified by high-sensitivity C-reactive protein (hsCRP; A; n=98) 
and serum amyloid A (SAA; B; n=97) concentrations that are above vs below the median concentration. C, Recurrence among 62 children 
with definite arteriopathy and follow-up vascular imaging, stratified by arteriopathy progression.
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